- Welcome and Program Overview
- Recent Data on Advances in Treatment for Newly Diagnosed and Relapsed/Refractory CLL/SLL
- Appraising Class Differences Between CLL/SLL Therapies
- Developing Effective Treatment Strategies for Your Patients Based on Current Data and NCCN Guideline® Recommendations
- Emerging Novel Management Approaches in CLL/SLL
- Audience Question and Answer Session and Closing Remarks
Sheraton Grand Chicago
Route 7 (Gate 21: North Bldg, level 1)
The National Comprehensive Cancer Network and Clinical Care Options, LLC are committed to providing a safe and healthy environment for all of our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. In addition, in accordance with ASCO’S COVID-19 protocols, all in-person learners will be asked to wear a mask and present their ASCO conference badge -OR- proof of vaccination AND government-issued ID to gain admittance to “Application of Individualized Treatment Strategies for CLL/SLL.”
For more information on ASCO’s vaccination and mask requirements, please visit: ASCO’s website.
*If you do not have your vaccination record card, find out other ways to verify you have been vaccinated.
Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.
William G. Wierda, MD, PhD
Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Asher Chanan-Khan, MBBS, MD
Chair, Department of Hematology/Oncology
Join our panel of experts to learn optimal treatment strategies for patients with CLL/SLL in this 1.5-hour satellite symposium, in person or with live simulcast!
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.
This educational program is intended for physicians, physician associates/physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.
Upon completion of this activity, participants should be able to:
- Design treatment plans for treatment-naive and relapsed/refractory CLL/SLL, including consideration of the agent’s toxicity profile, biomarkers, comorbidities, and patient preference
- Appraise intraclass differences among agents with the similar therapeutic target in CLL/SLL, regarding selectivity, target binding, efficacy, and adverse event profiles
- Develop strategies to address unique clinical challenges and leverage an understanding of the current data and NCCN Guideline to optimize outcomes for patients with CLL/SLL
- Evaluate the evolving role of measurable residual disease, allogeneic hematopoietic cell transplant, and CAR T-cell therapy
Joint Accreditation Statement
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
NCCN designates this educational activity for a maximum of 1.5 contact hours.
Continuing Pharmacy Education
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. Universal Activity Number: JA4008196-0000-22-038-L01-P
Type of Activity: Application
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.
Physician Associate/Physician Assistant Continuing Medical Education
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content will be reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, will be fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.